The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Amphastar Pharmaceuticals's Revenue for the
three
months ended in Mar. 2026 was $171.2 Mil. Amphastar Pharmaceuticals's average Accounts Receivable for the
three
months ended in Mar. 2026 was $145.7 Mil.
Hence, Amphastar Pharmaceuticals's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.17.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Amphastar Pharmaceuticals Receivables Turnover Related Terms
Amphastar Pharmaceuticals Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMPH vs ETON, PCRX, BIOA: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amphastar Pharmaceuticals (AMPH) has a Receivables Turnover of 1.17 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Amphastar Pharmaceuticals and its competitors. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #478 out of 943 companies in the Drug Manufacturers industry, placing it in the top 50.7%.
Is Amphastar Pharmaceuticals' Receivables Turnover too high?
Amphastar Pharmaceuticals' current Receivables Turnover is 1.17. The Drug Manufacturers industry median Receivables Turnover is 5.07. Amphastar Pharmaceuticals' value of 1.17 is 76.9% below this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #478 out of 943 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Receivables Turnover compare to ETON and PCRX?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #478 out of 943 companies for Receivables Turnover. This places Amphastar Pharmaceuticals in the lower half of its industry. The industry median Receivables Turnover is 5.07. Amphastar Pharmaceuticals' value of 1.17 is 76.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current Receivables Turnover of 1.17 is 76.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current Receivables Turnover is 1.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.81, compared to a current price of $19.66 — trading 59.7% below its estimated fair value. The current Receivables Turnover is 1.17 and 76.9% below the Drug Manufacturers industry median of 5.07. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Receivables Turnover is 1.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $19.66 is trading 59.7% below its estimated GF Value™ of $48.81.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
Receivables Turnover: 1.17
GF Value™: $48.81 vs. price of $19.66 (59.7% below fair value)
Industry Position: 76.9% below the Drug Manufacturers median (#478 of 943)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score
Get the complete analysis for AMPH
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
